Trichostatin A (TSA)

For research use only.

Catalog No.S1045

138 publications

Trichostatin A (TSA) Chemical Structure

Molecular Weight(MW): 302.4

Trichostatin A (TSA) is an HDAC inhibitor with IC50 of ~1.8 nM in cell-free assays.

Size Price Stock Quantity  
10mM (1mL in DMSO) USD 324 In stock
USD 247 In stock
USD 447 In stock
USD 870 In stock
Bulk Discount

Free Overnight Delivery on orders over $ 500
Next day delivery by 10:00 a.m. Order now.

Selleck's Trichostatin A (TSA) has been cited by 138 publications

Purity & Quality Control

Choose Selective HDAC Inhibitors

Biological Activity

Description Trichostatin A (TSA) is an HDAC inhibitor with IC50 of ~1.8 nM in cell-free assays.
Targets
HDAC [1]
(Cell-free assay)
~1.8 nM
In vitro

Trichostatin A inhibits the proliferation of eight breast carcinoma cell lines including MCF-7, T-47D, ZR-75-1, BT-474, MDA-MB-231, MDA-MB-453, CAL 51, and SK-BR-3 with mean IC50 of 124.4 nM (range, 26.4-308.1 nM), with more potency against cell lines that express ERα than the ERα-negative cell lines. Trichostatin A inhibits HDAC activity similarly in all the breast cancer cell lines with mean IC50 of 2.4 nM (range, 0.6-2.6 nM), and results in pronounced histone H4 hyperacetylation. [1] Unlike Trapoxin (TPX) and Chlamydocin which potently inhibit HDAC1 or HDAC4 but not HDAC6, Trichostatin A inhibits these HDACs to a similar extent with IC50 of 6 nM, 38 nM, and 8.6 nM, respectively. [2] Trichostatin A (100 ng/mL) treatment induces the expression of transforming growth factor β type II receptor (TβRII) in MIA PaCa-2 cells through the recruitment of p300 and PCAF into a Sp1-NF-Y HDAC complex that binds the DNA element of TβRII promoter, which is associated with a concomitant acetylation of Sp1 and an overall decrease in the amount of HDAC associated with the complex. [4]

Cell Data
Cell Lines Assay Type Concentration Incubation Time Formulation Activity Description PMID
HEK 293 NEfrdG9HfW6ldHnvckBCe3OjeR?= MWSwMlfPxE1? NYrsbldSOjSq NIflTIRmfGijbn;s M1jpSYVvcGGwY3XzJGVP[UNiYXPleJlt[XSrb36gZY5lKGmwY4LlZZNmeyCHTnHDJIFjfW6mYX7j[UBqdiC2aHWgeI91[WxiY3XscEBtgXOjdHWgZY5lKGG2IITo[UBk\WyuIIP1doZi[2V? MknNNlU4QDdyN{m=
TE13 NIDCNZJHfW6ldHnvckBCe3OjeR?= Ml3WNE4{|ryP MoXrNlRp NGDPeZh2eC2{ZXf1cIF1\XNiUlHTV2Y2SSCuZY\lcC=> NX7ub4JQOjV3N{m2OlU>
TE13 NWe4OWhVSXCxcITvd4l{KEG|c3H5 Mkj2NE4{|ryP M1rXWVI1cA>? NHTQdHNqdmirYnn0d{B1cGViY3XscEBxem:uaX\ldoF1cW:w NHLlcIMzPTV5OU[2OS=>
MEFs MlqxSpVv[3Srb36gRZN{[Xl? NVjMc5J1Pc7:TR?= M1fMO|E3cA>? MlnDbY5kemWjc3XzJJRp\SCHUFXDJIF1fGGlaH3lcpQtKFSrcjDk[YxqfmW{eTDhcoQhfGinIHXm[olkcWWwY4mgc4YheGWmZYP0ZYwh\m:{bXH0bY9v NG\qSmYzPTR6Mk[zOC=>
SW480  MlfGSpVv[3Srb36gRZN{[Xl? NULmTVVIOC5zzszN M4PMdVQ5cA>? NEfqSnFFVVOR NXe4UHFYemW4ZYLz[ZMhTU2W NXnJ[FhQOjV2M{S5PVc>
PC3  MWLGeY5kfGmxbjDBd5NigQ>? NILxbIwxNjIQvF2= M2TvOFQ5cA>? NYTZTlZHTE2VTx?= NWWzOJZlemW4ZYLz[ZMhTU2W M1P5WVI2PDN2OUm3
SW480  MXPGeY5kfGmxbjDBd5NigQ>? NV70NZROOC5zzszN M3TCcFQ5cA>? Mmq2SG1UVw>? M1fSO4F1fGWwdXH0[ZMhcW64YYPpc44h[W6mIH3p[5JifGmxbh?= M{DJUFI2PDN2OUm3
PC3  M4L6V2Z2dmO2aX;uJGF{e2G7 NUPicppTOC5zzszN NELFTYs1QGh? M4\XbGROW09? NIntS3FifHSnboXheIV{KGmwdnHzbY9vKGGwZDDtbYdz[XSrb36= MlXVNlU1OzR7OUe=
SW480  MUHGeY5kfGmxbjDBd5NigQ>? NHTIPGcxNjIQvF2= NGm2N2o1QGh? M3LXdGROW09? MkjqbY5lfWOnczDpcoNz\WG|ZTDv[kBJTEGFMTDhcoQhUESDQ{Kgc44hW2y3ZzDn[Y5meyCycn;tc5Rmeg>? MkfGNlU1OzR7OUe=
PC3  MlzSSpVv[3Srb36gRZN{[Xl? MkC2NE4y|ryP MXq0PIg> NU\6TpNJTE2VTx?= MkX1bY5lfWOnczDpcoNz\WG|ZTDv[kBJTEGFMTDhcoQhUESDQ{Kgc44hW2y3ZzDn[Y5meyCycn;tc5Rmeg>? NH7tTowzPTR|NEm5Oy=>
A431 Mn\xRZBweHSxc3nzJGF{e2G7 NXnLclVZOi9zMD:1NE8yODCwTR?= MX:0PIg> MUXEUXNQ MVvpcohq[mm2czD0bIUh[2WubDDndo94fGh? M4P0cVI2OzdzME[5
A431 NUjFS|NnTnWwY4Tpc44hSXO|YYm= NXL2flFrPTCwTR?= NGDXPVMzNzZxMUKvNlRp NUfDSmhwTE2VTx?= NYD1Z5Zn[WO2aY\heIV{KHB{MTDhcoQhcW6qaXLpeJMhSVSIMzDlfJBz\XO|aX;u NYTWN2huOjV|N{GwOlk>
MDA-MB-231 MkPKS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NXPJbJRZOC14MEDuUS=> M3zFbVI1cA>? MlG5SG1UVw>? NH[0eHpKSzVyIH;mJFExOG6P NFXqSnEzPTF7MkeyNS=>
MCF7 M3WxT2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M{TOZlAuPjBybl2= NGDybo4zPGh? NXOxTG1NTE2VTx?= MnvGTWM2OCCxZjC3OY5O MYmyOVE6Ojd{MR?=
SKOV-3 NV\4fItMT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MkDFNU0yOM7:TR?= NF;LbYwzPGh? MlXxSG1UVw>? MXPJR|UxKG:oIEWuOu69VQ>? MX:yOVE3QTR7MR?=
A549 NGS3UHNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NFrtUY8yNTFyzszN MmfvNlRp M1nrRWROW09? MWjJR|UxKG:oIEOuNu69VQ>? M1XSflI2OTZ7NEmx
SKOV-3 M2H2[2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NHXEb3IxNjFvMd88US=> MVq0PIg> MkjaSG1UVw>? NEW5N4hKSzVyIH;mJFAvP87:TR?= MVmyOVE3QTR7MR?=
A549 Mlj0S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M2LIU|AvOS1zzszN MmHVOFhp M{jLemROW09? NXTyc|REUUN3MDDv[kAxNjJ6zszN M3nSWVI2OTZ7NEmx
SKOV-3 M{LH[Gdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MWCwMlAyNTBwOd88US=> NET1fWU4Omh? M3y1cWROW09? MVjJR|UxKG:oIECuN|LPxE1? MY[yOVE3QTR7MR?=
A549 MXjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NVXGZmhHOC5yMT2wMlnPxE1? NHywZXU4Omh? NHq1S5NFVVOR NEDlN5VKSzVyIH;mJFAvODcQvF2= MoOyNlUyPjl2OUG=
HeLa MXTGeY5kfGmxbjDBd5NigQ>? NGHadlMzPTCwTR?= MnTnNVZp NYLFdYkyTE2VTx?= NFvlO3ZqdmO{ZXHz[ZMhS1mSMVGxJI1TVkFiZYjwdoV{e2mxbtMg NUTPOo1TOjVzMU[2PFg>
CNE2 MV3Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M2jrRlExOC14MEDuUS=> NWXpSmZPOjRxNEivO|Jp MXLpcohq[mm2czD0bIUheHKxbHnm[ZJifGmxbjDpckBiKHSrbXWtJIFv\CCmb4PlMYRmeGWwZHXueEBu[W6wZYK= NXXqO|hyOjR7Nkm5NFE>
PC3 MlfzS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NEfHPGIyODBvMUCwNI5O NGTiNIozPGh? M3zPfGlEPTBib3[gN|Axdk1? NXXnbHFwOjR6NUS2OVg>
LNCaP NFTsNJpIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MXmxNFAuOTByMH7N NYrEPYhvOjSq MXzJR|UxKG:oIEOwNI5O NVPCTIN2OjR6NUS2OVg>
HeLa  M4TubGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NIXsW5Mz|ryP NVfOb3dRPDiq NXTmcJVQ\GWlcnXhd4V{KGOnbHygeoli[mmuaYT5JIFjd3W2IEK1KS=> MWSyOFg1PjF|NR?=
HMEC-1  M4W4fmZ2dmO2aX;uJGF{e2G7 NES0blM{ODCwTR?= NYDIfmpnOjSq NV\ZfYJKcW6lcnXhd4V{KGW6cILld5Nqd25ib3dCpHZGT0[UM9MgcXJPSQ>? NWTPb2lkOjR5MUC2N|E>
HeLa MkL6SpVv[3Srb36gRZN{[Xl? NGewZmwydU1? MV6wMlVp NUHLToZ4[WKxbHnzbIV{KHSqZTD0c5RidCCKRFHDJIFkfGm4aYT5 NUTtWpVUOjR5MEe0O|Q>
ACP02 NUHrWG9ST3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MX[yOVAwOzVyL{WwNI5O M1vCfFI1cA>? M2XYOIRm[3KnYYPld{Bk\WyuII\pZYJqdGm2eTDv[kBieHC{b4jpcYF1\Wy7IEewxsAmKGG2IEK1NOKhdk1? MVKyOFY3QDV2Nx?=
ACP03 MoT0S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MYCyOVAwOzVyL{WwNI5O NFyyXFAzPGh? Mnni[IVkemWjc3XzJINmdGxidnnhZoltcXS7IH;mJIFxeHKxeHntZZRmdHliN{FCpEUh[XRiMkWwxsBvVQ>? NHXtdXozPDZ4OEW0Oy=>
U87 GBM NYLUSVdyT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NFPCO5MyODBxM{CwM|UxOCCwTR?= NUHlOoo2PzJiaB?= MVixNFAmKGW2aHHuc4w> M4G2bpJm\HWlZYOgcYVidiClZXzsJI52dWKncjDifUA{OSxiNUSsJIFv\CB3ONMgKS=> NHP5cW0zPDR4NEi0NS=>
U87 GBM NU[3UpVyTnWwY4Tpc44hSXO|YYm= M1HlS|ExOC93MECgUo0> NEL3R4g1QCCq M2jUcVExOCViZYToZY5wdA>? MUDJcoR2[2W|IGPlcoV{[2WwY3WtUIls\SCDbITldoF1cW:wczDpckBPfWOuZXHyJG1wenCqb3zv[5k> MojzNlQ1PjR6NEG=
RPE M4LJ[2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NFXqVJAxNjJxMD60M|AvQC9zIN88US=> NYH3W|lTOjRxNEivO|IhcA>? NFjhWVdFVVOR NVXhNWtncW6qaXLpeJMhfGinIIDyc4xq\mW{YYTpc44h[nliY3XscEBkgWOuZTDhdpJme3R? NVm3XVFxOjR2NU[2NFI>
HT29  M4\lUmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NFLvfFEyQDBibl2= MoHHO|IhcA>? M2XoN2lEPTBib3[gNVgxKG6P MYmyOFM3QDJ4NR?=
hMSCs NHzESFVHfW6ldHnvckBCe3OjeR?= MVe2MlI2KG6P NXLY[JZ2OjRiaB?= M3zC[mROW09? NVX6T3R6e3SjYnnsbZpmeyCKaYP0c45mKEGlZYT5cIF1cW:wIHHu[EB1cGViRYjwdoV{e2mxbjDv[kBRdHW{aYDveIVvfCCJZX7ldy=> NEm0TYozPDNzMkO1Oi=>
Huh7  MoXqSpVv[3Srb36gRZN{[Xl? NYfvflZvOC5zL{CuOU8yNjBizszN MkHWNlRp Ml7wd5VxeHKnc4Pld{B[XEiGQ{Kg[4Vv\SCneIDy[ZN{cW:w MYiyOFI3QTZ5Mh?=
SKOV3 MoHnS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NYn3PXp5OC5yNT2yJO69VQ>? M37oVFExNzJ2L{S4JIg> M{DGcmROW09? NHjCRXhu\WSrYYTld{Boem:5dHigZZJz\XO2IHnuJIEh[2:wY3XueJJifGmxbj2gZY5lKHSrbXWt[IVx\W6mZX70JI1idm6nch?= MV2yOFIzOzhyMR?=
A2780 NH;qVWdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NEPXeHAxNjB3LUKg{txO MYCxNE8zPC92ODDo M{K3b2ROW09? M1fsOo1m\GmjdHXzJIdzd3e2aDDhdpJme3RiaX6gZUBkd26lZX70doF1cW:wLTDhcoQhfGmvZT3k[ZBmdmSnboSgcYFvdmW{ NF;YVlMzPDJ{M{iwNS=>
SRA01/04  NF7xZ5dIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= Mmn6NE4zKM7:TR?= MVW0PEBp NFHvWYZFVVOR NUH0fZBie3WycILld5NmeyClZXzsJJBzd2yrZnXyZZRqd25idHjyc5VocCC|dYDwdoV{e2mwZzD0bIUhWEl|Sz;Bb5QtKHB|OF3BVGsh[W6mIFXST|EwOiC|aXfuZYxqdmdicHH0bJdigXN? M13tclI1OTV5OEe4
HLEB3 M{DKVWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MXiwMlIh|ryP MYG0PEBp Ml7iSG1UVw>? MWnzeZBxemW|c3XzJINmdGxicILvcIln\XKjdHnvckB1cHKxdXfoJJN2eHC{ZYPzbY5oKHSqZTDQTVNMN0GtdDygdFM5VUGSSzDhcoQhTVKNMT:yJJNq\26jbHnu[{Bx[XSqd3H5dy=> MkfsNlQyPTd6N{i=
SRA01/04  NHLM[pVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M4PEdVAvPC9yLkig{txO NHzLVWk1QCCq NX7mbYR[TE2VTx?= NWrzWmM6cW6mdXPld{Bk\WyuIHHwc5B1d3Orcx?= NHfqeJgzPDF3N{i3PC=>
HLEB3 M1nUTGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MnXONE41NzBwODFOwG0> MnL1OFghcA>? NVXTSlVLTE2VTx?= NGXkc|ZqdmS3Y3XzJINmdGxiYYDvdJRwe2m| M13TS|I1OTV5OEe4
HCT116 MYXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MV:wMlIh|ryP MX6xNkBp MYPlcohidmOnczDj[YxtKGGyb4D0c5NqeyCrbnT1Z4VlKGK7IILh[IlifGmxbh?= MYWyOFEzOjJ|MR?=
CA46 NITveVhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NXHVPIFZOy94L{GyM|I1NzR6IH7N MnPOOFghcA>? M1\uTIlvcGmkaYTzJJRp\SClZXzsJJBzd2yrZnXyZZRqd25iYYSgNlQh[W6mIES4JI5OyqB? MnHmNlQxPjR7NUG=
PMNs MoSwSpVv[3Srb36gRZN{[Xl? MYqzNEBvVQ>? Mkf5OFghcA>? NXLDXXNZcW6qaXLpeJMh\W[oZYLvZ5l1d3OrczygTGRCSyCjY4Tpeol1gSCjbnSgVoFkKGGldHn2bZR6 M1zkV|I{QTh6NkG3
H1299 Mlr1S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MUSxxsDPxE4EoB?= NX[xcXAzOjRxNEivO|IhcA>? NHu1WlZmfGijbn;s NFLDRpRqdmO{ZXHz[ZMh[2WubDDk[YF1cCCjZoTldkAzPGh? NYXSOo9{OjN7MU[2NFk>
A549 MnTZS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MnPZNE4zPS9yLkWvNUDPxE1? NYXWUIxTOjRxNEivO|IhcA>? M{jM[YV1cGGwb3y= MlLubY5pcWKrdIOgeIhmKGOnbHyg[5Jwf3SqIHnuJINwdmOnboTyZZRqd25iYX7kJJRqdWVvZHXw[Y5l\W62IH3hco5meg>? MWqyN|g3Pzl7MR?=
H1299 M3fkbmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NYS5R2oxOC5{NT:wMlUwOSEQvF2= MYOyOE81QC95MjDo NFzWVmdmfGijbn;s M1nEe4lvcGmkaYTzJJRp\SClZXzsJIdzd3e2aDDpckBkd26lZX70doF1cW:wIHHu[EB1cW2nLXTldIVv\GWwdDDtZY5v\XJ? M3TnSlI{QDZ5OUmx
A549 M{\2SWFxd3C2b4Ppd{BCe3OjeR?= MmLnNE42NzFizszN MVO0PEBp Mn3V[ZRp[W6xbB?= NEWzcY1qdmS3Y3XzJINmdGxiYYDvdJRwe2m| MYqyN|g3Pzl7MR?=
H1299 MWDBdI9xfG:|aYOgRZN{[Xl? Mnq2NE42NzFizszN M1znbVQ5KGh? M1H4OYV1cGGwb3y= NXuySXp6cW6mdXPld{Bk\WyuIHHwc5B1d3Orcx?= MYeyN|g3Pzl7MR?=
SUM149PT Ml33S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NV;OfZZ6Oi95LkWvNVAh|ryP NYDBTYpoPDhiaB?= NGT3SmlFVVOR MUfpcoR2[2W|IHPlcIwh\GWjdHigZZQhOiEQvF2gbY5{\W6|aYTpeoVtgQ>? NEG4WnozOzd7Mk[zPC=>
SUM190PT MXrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MoK0OVAwOTByL{K1NEBvVQ>? Ml\zOFghcA>? MWfEUXNQ NFHZZVRqdmS3Y3XzJINmdGxiZHXheIgh[XRiNUCgcm0he2Wwc3n0bZZmdHl? NEWwbG4zOzd7Mk[zPC=>
HCT1 NFLsbFlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NXnkXVdsOC5{L{GuNE82NjBizszN MljHNVIwOjRxM{[vOFghcA>? NETVe41qdmS3Y3XzJINmdGxiZHXheIghcW5iY3;uZ4VvfHKjdHnvck0h[W6mIITpcYUu\GWyZX7k[Y51KG2jbn7ldi=> MYCyN|c4ODByMB?=
Lovo MYLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MUOwMlIwOS5yL{WuNEDPxE1? NVPJPVRiOTJxMkSvN|YwPDhiaB?= MXPpcoR2[2W|IHPlcIwh\GWjdHigbY4h[2:wY3XueJJifGmxbj2gZY5lKHSrbXWt[IVx\W6mZX70JI1idm6nch?= Ml\NNlM4PzByMEC=
AGS MXrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MkfnNE4xOTVvMTFOwG0> NXPYWo9xPzJiaB?= MXnpcoR2[2W|IHPlcIwh\GWjdHigZ49v[2WwdILheIlwdiCmZYDlcoRmdnSueR?= MXyyN|c1PTB{NB?=
Huh7 NVf6OYE2T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M33FOlEh|ryP NYfUV5c6OjRiaB?= MWHEUXNQ NEDuTG1z\WS3Y3XzJIFjd3W2IEKwKUB3cWGkaXzpeJnDqA>? MXmyN|Y1Ozl|Mx?=
ECC1 NG\NfmdHfW6ldHnvckBCe3OjeR?= MYi1NFAhdk1? MmHoOUBl MVrEUXNQ NFu0Z2RqdmS3Y3XzJGwyS0GPwrDlfJBz\XO|aX;uJINwNXS{ZXH0cYVvfCC5aYToJFUuSXqjQx?= M{nQSlI{PTNyN{[5
HEC1A NX62NIZ1TnWwY4Tpc44hSXO|YYm= MWm1NFAhdk1? NHjhPGY2KGR? NUHqUGlQTE2VTx?= NIXa[4pqdmS3Y3XzJGwyS0GPwrDlfJBz\XO|aX;uJINwNXS{ZXH0cYVvfCC5aYToJFUuSXqjQx?= NVnIbZQ2OjN3M{C3Olk>
EN1 NF3leVVHfW6ldHnvckBCe3OjeR?= NXfxN2JvPTByIH7N M4HlflUh\A>? MXnEUXNQ MnLybY5lfWOnczDMNWNCVcLiZYjwdoV{e2mxbjDjc{11emWjdH3lcpQhf2m2aDC1MWF7[UN? NHv0ZoEzOzV|MEe2PS=>
MFE296 MUHGeY5kfGmxbjDBd5NigQ>? NV;6SlB4PTByIH7N MoW5OUBl Mn3MSG1UVw>? M4DjbIlv\HWlZYOgUFFESU4EoHX4dJJme3Orb36gZ48ufHKnYYTt[Y51KHerdHigOU1CgmGF NFv5fGYzOzV|MEe2PS=>
HASMCs MWXGeY5kfGmxbjDBd5NigQ>? NFjGd4MxNTVyMDDuUS=> MkDQOkBl Mofw[I94di2{ZXf1cIF1\XNidHjlJIV5eHKnc4Ppc44hd2ZiSFHER{BidmRiY3XscEB3cWGkaXzpeJk> NUXudpJ4OjN3MUi0Olc>
U373 NULRNGZtTnWwY4Tpc44hSXO|YYm= MXmwMlI2NzBwNT:xJO69VQ>? NHHOe3ozPCCq MXzpcoNz\WG|ZYOgVHIuSiCneIDy[ZN{cW:wIHPvMZRz\WG2bXXueEB4cXSqIEXBfoFlSw>? MkLnNlM1PzRzN{G=
ARN8  M3flUGZ2dmO2aX;uJGF{e2G7 NI\4ZWwxNjB3LUKg{txO MXyyOEBp NITpN3Nz\WS3Y3XzJJRp\SCrbnT1Z5Rqd25ib3[gdFU{NWSncHXu[IVvfCCpZX7ld{BjgSCQdYTsbY4uOw>? NY\MdIdCOjN2N{C1OFA>
MCF7 MXvGeY5kfGmxbjDBd5NigQ>? MofGNE4xPS1{IN88US=> MkDtNlQhcA>? MUXy[YR2[2W|IITo[UBqdmS3Y4Tpc44hd2ZicEWzMYRmeGWwZHXueEBo\W6nczDifUBPfXSuaX6tNy=> NUTRfZBMOjN2N{C1OFA>
H1299  MYXGeY5kfGmxbjDBd5NigQ>? NIC0TVgxNjN|4pETNeKhyrWP MoH3NlQwPDhiaB?= MojISG1UVw>? M1fXTolv[3KnYYPld{BGNWOjZHjldolvKHC{b4TlbY4hdGW4ZXzzJIRwe2ViZHXw[Y5l\W62bIm= NVfoRo5VOjN2NkG5O|U>
H1299 MoX1SpVv[3Srb36gRZN{[Xl? MkK1NE42KM7:TR?= NHHjOmk1QCCq NH\4UYtFVVOR NYe2OpdtcW6qaXLpeJMhfGinIH3p[5JifG:{eTDwc5RmdnSrYXygZ49u[mmwZTD3bZRpKHOrbHnibY5qdg>? Mo\RNlM1PjF7N{W=
H1299 MmLCSpVv[3Srb36gRZN{[Xl? MknyNE42KM7:TR?= M{m1U|Q5KGh? NIjI[pVFVVOR NYGxfnZmcW6qaXLpeJMhfGinIHnueoF{cX[nbnXzd:KhKGOxbXLpcoUhf2m2aDDzbYxq[mmwaX6= MWKyN|Q3OTl5NR?=
MG-63  NUfGR45NT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NWDHPZQ3OC5|IN88US=> MmnxNVIuQTZiaB?= NID1OnJFVVOR NF30dpVqdmirYnn0d{B1cGViY3XscEBoem:5dHigZ48ufHKnYYTt[Y51KHerdHigcYV1\m:{bXnu NV3JfolUOjN2NUG4NVc>
LM8 NIrQXXpIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MmfJNE4{KM7:TR?= NFHsT|IyOi17NjDo MVPEUXNQ M3XsNolvcGmkaYTzJJRp\SClZXzsJIdzd3e2aDDjc{11emWjdH3lcpQhf2m2aDDt[ZRnd3KvaX6= M4[xXlI{PDVzOEG3
K562 NFrLSFBHfW6ldHnvckBCe3OjeR?= MXSwMlUh|ryP MW[yOEBp M120T4V1cGGwb3y= NXyyPVZX\GWlcnXhd4V{KHSqZTDlcpp6dWViYXP0bZZqfHlib3[gTGRCS3NiY3:teJJm[XSvZX70JJdqfGhiY4XyZ5VucW5? MX:yN|Q{ODl3Nx?=
HEL MoL1SpVv[3Srb36gRZN{[Xl? M3\6OlAvPSEQvF2= NI\wXpozPCCq M1vhboV1cGGwb3y= M{LjdIRm[3KnYYPld{B1cGViZX76fY1mKGGldHn2bZR6KG:oIFjERWN{KGOxLYTy[YF1dWWwdDD3bZRpKGO3cnP1cYlv MlHENlM1OzB7NUe=
HL60 MUPBdI9xfG:|aYOgRZN{[Xl? NXTMRWZZOSEQvF2= MV:yOEBp Mm\MbY5lfWOnc9MgZ4VtdCCmZXH0bC=> NXWyeZBjOjN2MEC1NVk>
KG1 MonIRZBweHSxc3nzJGF{e2G7 NFzvbWQyKM7:TR?= MoHNNlQhcA>? MWnpcoR2[2W|wrDj[YxtKGSnYYTo M{jiRlI{PDByNUG5
Kazumi NHfHe2dCeG:ydH;zbZMhSXO|YYm= MnLzNUDPxE1? M2[3NVI1KGh? MYrpcoR2[2W|wrDj[YxtKGSnYYTo Ml;uNlM1ODB3MUm=
K562 NWPBR2VnSXCxcITvd4l{KEG|c3H5 M4rx[FEh|ryP MmDzNlQhcA>? M1HjcIlv\HWlZYRCpINmdGxiZHXheIg> M2LuV|I{PDByNUG5
THP1 NW\XeZVPSXCxcITvd4l{KEG|c3H5 MXOxJO69VQ>? MUKyOEBp MmPqbY5lfWOnc9MgZ4VtdCCmZXH0bC=> NEnSTIEzOzRyMEWxPS=>
SH-SY5Y NY\qfHdlTnWwY4Tpc44hSXO|YYm= NWL6bWZQOjVyIH7N Mo[xNVYhcA>? MX\jbIFv\2W|IHX4dJJme3Orb36gdIF1fGW{bjDv[kBo\W6nczDpcpZwdH[nZDDpckBkcG:uZYP0[ZJwdCC|eX70bIV{cXNuIIXweIFs\SCjbnSg[YZndHW6 M37UV|I{OzJ4NEKy
HEK293 MXfGeY5kfGmxbjDBd5NigQ>? MUKxJOK2VcLi NFzGXIIyQCCqwrC= NH6yWJBqdmirYnn0d{B1cGVia3HsbZJqdi15LX3l[IlifGWmIILlZ5J2cXSvZX70JI9nKHO7boDobYxqdi1zIHHn[5Jm\2G2ZYOgbY51dyCjZ3fy[ZNwdWW| M{P5eVI{Ojh2OES4
HTK MWTGeY5kfGmxbjDBd5NigQ>? M3rsSlQxOCCwTR?= NEfEZVE4OiCq NUHhcJBicW6qaXLpeJMhXEeILd8y5qCUUW6mdXPl[EBOgW:oaXLyc4Jt[XO2IFTp[oZmemWwdHnheIlwdg>? MYiyN|I5PDByMh?=
HTK MmH2SpVv[3Srb36gRZN{[Xl? MlrKNVAxNThyMH7N NX\JZZV4PzJiaB?= Ml;DZoxw[2u|IGTHSk3PuuLCk1nu[JVk\WRiUl;TJIFv\CCKMl:yxsBC[2O3bYXsZZRqd25? NWnXd5NJOjN{OESwNFI>
Caco-2  M4LyRmZ2dmO2aX;uJGF{e2G7 NHjMZY0yKML3TdMg M1X2RVI1KGh? NF\WcmZl\WO{ZXHz[ZMhW0WUVDDwdo91\WmwIHX4dJJme3Orb36= M33CUFI{OTl3MEew
HeLa MX;Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NGHRWGIyODBibl2= MViyOEBp NVT4dXplTE2VTx?= M{i5eWlEPTBib3[gNVAxdk1? Mlv6NlMyPjV5NEi=
HeLa NIHGfnBIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NEjrfoE1OCCwTR?= MkXEOFghcA>? MXLEUXNQ NXP5UVAzUUN3MDDv[kA1OG6P M{LpWlI{OTZ3N{S4
HeLa NUn4V3FCT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MlL6NlAhdk1? NUXVUVFRPzJiaB?= NF\WWm5FVVOR NVyycpFtUUN3MDDv[kAzOG6P M2jnc|I{OTZ3N{S4
HeLa M1HlT2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NFL2Z4oyOC9|MD:1NEBvVQ>? NHPUbYM4OiCq MmLESG1UVw>? MoXObY5kemWjc3XzJJRp\SCwdX3i[ZIhd2ZiTV3QJEjPnM7qbTmgcI9{eyClZXzsd{Bld3OnIHTldIVv\GWwdHz5 MnXhNlMyPjV5NEi=
MDA-MB-231 NILN[IRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NIX2XFgzPS12MECgcm0> NUTTUWo5PDhiaB?= NGnHW2xKSzVyIH;mJFI3Oy5{bl5CpC=> NUDne2ZrOjNyNUWxPVg>
MCF-7  NIfwcZBIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NF\BfoQzPS12MECgcm0> NHfQS201QCCq M4XmNmlEPTBib3[gNlIxNjSwTR?= M2fCZ|I{ODV3MUm4
ECC-1  NVjSOIhMT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NFjpPIQyODBibl2= NEG2cWEzPCCq Mo\s[ZRp[W6xbB?= M3vKNIlv[3KnYYPld{B1cGVicILvdI9zfGmxbjDv[kBieG:ydH;0bYMhdnWlbHXpJJRwKDN3JR?= NUO1VndSOjNyMki4NFM>
HEC-1A NHnpNJBIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NX[xfVRJOTByIH7N NECz[3ozPCCq MWrleIhidm:u NEnQVWRqdmO{ZXHz[ZMhfGinIIDyc5BwenSrb36gc4Yh[XCxcITveIlkKG63Y3zlbUB1dyB|OTW= MVqyN|AzQDhyMx?=
NHAC-kn NX25do5NT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NVfu[3BmOTBxMUCwM|UxOCCwTR?= M1rnVFEzKGh? NIDzV5NFVVOR M1LnTmlEPTBib3[gOVAxdk1? MXSyN|AyPzh5MR?=
A549 NIf1SmpIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NIfSOHEzPTBibl2= MmPNOk04OiCq Mn3vSG1UVw>? MVfjZZV{\XNiYTDndoVifGW{IHnubIljcXSxcomg[YZn\WO2IHPvcYJqdmVid3n0bEBVYFRib4Kg[ZJtd3Srbnni MVWyNlk6PDd6MB?=
MG-63 MWDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NVLPUWNKOzByIH7N MojZNVIhcA>? MnXySG1UVw>? MVPpcohq[mm2czD0bIUh[2WubDDndo94fGhidH:gPFYm MWOyNlc6QTN|OB?=
MG-63 MUTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NY\jcYJmOzByIH7N NUHhVZZVOjRiaB?= MnLjSG1UVw>? MYrpcohq[mm2czD0bIUh[2WubDDndo94fGhidH:gOlcm NUjOUIlxOjJ5OUmzN|g>
MG-63 MkLYS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M{HHSlMxOCCwTR?= M37PPFQ5KGh? NYHGT4Z1TE2VTx?= NXS2PHl1cW6qaXLpeJMhfGinIHPlcIwh\3Kxd4ToJJRwKDV4JR?= NUjSS4VqOjJ5OUmzN|g>
HL60  MWfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MWqxOVAuOzVyIH7N M3q1ZlI1KGh? M2rrUolv[3KnYYPld{Bk\WyuIHHwc5B1d3Orc9Mge4hmdiClb37j[Y51emG2aX;ud{BpcWeqZYKgeIhidiB{NUCgcm0> NXLqWVR3OjJ5NUO3N|k>
U937 MX;Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NUX4eoFqOTVyLUO1NEBvVQ>? M3u2UlI1KGh? MUXpcoNz\WG|ZYOgZ4VtdCCjcH;weI9{cXQEoIfo[Y4h[2:wY3XueJJifGmxboOgbIlocGW{IIToZY4hOjVyIH7N M1jRN|IzPzV|N{O5
SCC-6 MV3Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MXSyNFAuOzJyMDDuUS=> NEi4OGsyOi9{ND:0PEBp MmXFSG1UVw>? M{S4NIlvcGmkaYTzJJRp\SCycn;sbYZmemG2aX;uJI9nKFOFQz22JINmdGy|IHnuJIEh\G:|ZT2gZY5lKHSrbXWt[IVx\W6mZX70JI1idm6nch?= MlHENlI2PTJ|MkG=
U87  MmjCS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M36zNlExOC1|MECgcoc> NHX1bY4zPCCq Mor3bY5pcWKrdIOgeIhmKGOnbHyg[5Jwf3SqIITvJFczLSBiYYSgNlAxdmd? MVGyNlI4ODh2OR?=
K562 M4XjRWZ2dmO2aX;uJGF{e2G7 MVKxJO69VQ>? NHv0VZQyOiCq NXX0fmVUTE2VTx?= NWnwVYpV\W6qYX7j[ZMhfGinIHX4dJJme3Orb36gc4YhWlWQWEOgbY5lfWOnZDDifUA2NWG8YT3D[HI> NVPzZnBOOjJzN{mxPVg>
Reh NW\ZNoxZTnWwY4Tpc44hSXO|YYm= NIe1SIsxNjNxMTFOwG0> MVOxNkBp MUHEUXNQ M3XMRoVvcGGwY3XzJJRp\SCneIDy[ZN{cW:wIH;mJHJWVlh|IHnu[JVk\WRiYomgOU1igmFvQ3TS MoO4NlIyPzlzOUi=

... Click to View More Cell Line Experimental Data

Assay
Methods Test Index PMID
Western blot
EGFR / STAT3 ; 

PubMed: 31289542     


Expression of EGFR and STAT3 in PC3 cells treated with TSA. PC3 cells were plated in 6-cm dishes, and 0.25, 0.5 or 1 µM TSA was added for 24 h. DMSO was added into the control group wells. Cells were collected and lysed with lysis buffer and the protein expression analyzed via western blotting.

Cyclin D1 / CDK6 / CDK4 / p-RB / RB; 

PubMed: 31289542     


Expression of cyclin D1, CDK6, CDK4 and RB, and the phosphorylation of RB, was detected in PC3 cells treated with TSA for 24 h. 

MMP-1 / MMP-3 / MMP-13 / TIMP-1; 

PubMed: 27431944     


Chondrocytes were pretreated with increasing concentrations of TSA for 2 h, followed by stimulation with 5 ng/ml IL-1β for 24 h.

Acetyl-H3 (Lys27) / H3 (96C10) / Acetyl-H4(Lys8) / H4(L64C1); 

PubMed: 27431944     


Chondrocytes were treated with increasing concentrations of TSA for 24 h.

α-H3Ac / α-H4Ac / α-H3K9Ac / α-H3K9 S10 / α-H3K4 me / α-H3K4 me2 / α-H3K9 me2; 

PubMed: 23802098     


Histone acetylation occurs directly at the promoter region of IL-23R. The ChIP assay demonstrates that TSA treatment results in an increase in the acetylation of histone H3 and H4. A549 cells were cultured in the presence or absence of TSA (250 ng/mL) for a period of 24 h. Subsequently, a ChIP assay was performed using the following antibodies; pan acetyl-histone H3 (H3Ac), pan acetyl-histone H4 (H4Ac), acetyl-histone H3 Lys 9 (H3K9Ac), acetyl-histone H3 Lys 9/14 (H3K9/14ac), acetyl-histone H3 Lys 9 phosphoSer10 (H3K9S10), methyl-histone H3 Lys 4 (H3K4Me), di methyl-histone H3 Lys 4 (H3K4Me2), and di methyl-histone H3 Lys 9 (H3K9Me2). Input DNA serves as a positive control as recommended by the manufacturer (Diagenode). A no antibody control was included to test for non-specific binding (UT, untreated; TSA, Trichostatin A).

31289542 27431944 23802098
Immunofluorescence
α-C/EBPβ / α-HP1α ; 

PubMed: 21122806     


3T3-L1 preadipocytes were grown on coverslips for three days and induced to differentiate by treatment with MDI (48 h) in the presence of vehicle (-TSA) or 87 nM Trichostatin A (+TSA). Under these experimental conditions: A-H Cells were fixed and permeabilized in cold methanol, subjected to IIF with the indicated antibodies, and nuclei were counterstained with DAPI. Scale bar, 5 μm. 

α-HDAC1 ; 

PubMed: 29045501     


MCF-7 cells were treated with indicated concentrations of trichostatin A (optical sections E-H, respectively) for 12 hours, fixed, permeabilized and optical sections were obtained by laser scanning confocal microscopy. Fluorescence signal for HDAC1 is shown in green (left panels), DAPI staining is shown in blue (middle panels), and merged optical sections are shown in the right panels.

α-tubulin / acetylated histone 3; 

PubMed: 27957719     


Immunocytochemistry for acetylated α-tubulin (red) and acetylated histone 3 (green) on N2a cells treated with 1 μM TSA, ACY-738, and ACY-775.

21122806 29045501 27957719
Growth inhibition assay
Cell viability (A549 cells); 

PubMed: 27571418     


Cytotoxicity of histamine determined by MTT assay in A549 cells.

Cell viability (MDA-MB-231 cells); 

PubMed: 27548148     


The human breast cancer cells (MDA-MB-231) were incubated with various concentrations of TSA (0–300 nM) for 24 h. Cell viability was measured by WST-8.

Cell viability (PC3 cells); 

PubMed: 31289542     


PC3 cells were plated in a 96-well plate and treated with different doses of TSA (0, 0.25, 0.5 and 1 µM) for 72 h; an MTT assay was used to measure the effects of TSA on PC3 cell proliferation.

27571418 27548148 31289542
In vivo Administration of Trichostatin A at 0.5 mg/kg for 4 weeks displays potent antitumor activity in the N-methyl-N-nitrosourea carcinogen-induced rat mammary carcinoma model, without any measurable toxicity at doses up to 5 mg/kg. [1] Single intraperitoneal doses of 10 mg/kg Trichostatin A in nontransgenic and spinal muscular atrophy (SMA) model mice results in increased levels of acetylated H3 and H4 histones and modest increases in survival motor neuron (SMN) gene expression. Administration of Trichostatin A at 10 mg/kg/day improves survival, attenuates weight loss, and enhances motor behavior in the SMA model mice. [5]

Protocol

Kinase Assay:

[1]

- Collapse

In vitro HDAC activity:

Total cellular extracts are prepared from each breast cancer cell line (MCF-7, T-47D, ZR-75-1, BT-474, MDA-MB-231, MDA-MB-453, CAL 51, or SK-BR-3). A 20 μL crude cell extract (~2.5 ×105 cells), in the presence of varying concentrations of Trichostatin A in 0.1% (v/v) ethanol or 0.1% (v/v) ethanol as vehicle control, are incubated for 60 minutes at 25 °C with 1 μL (~1.5 × 106 cpm) of [3H]acetyl-labeled histone H4 peptide substrate (NH2-terminal residues 2-20) that has been acetylated with [3H]acetic acid, sodium salt (3.7 GBq/mmol) by an in vitro incorporation method. Each 200 μL reaction is quenched with 50 μL of 1 M HCl/0.16 M acetic acid and extracted with 600 μL of ethyl acetate, and released [3H]acetate is quantified by scintillation counting. IC50 values are determined graphically using nonlinear regression to fit inhibition data to the appropriate dose-response curve.
Cell Research:

[1]

- Collapse
  • Cell lines: MCF-7, T-47D, ZR-75-1, BT-474, MDA-MB-231, MDA-MB-453, CAL 51, and SK-BR-3
  • Concentrations: Dissolved in absolute ethanol, final concentrations ~10 μM
  • Incubation Time: 96 hours
  • Method:

    Cells are exposed to various concentrations of Trichostatin A for 96 hours. After treatment, cell proliferation is estimated using the sulforhodamine B colorimetric assay. Cell viability is determined by trypan blue exclusion.


    (Only for Reference)
Animal Research:

[1]

- Collapse
  • Animal Models: Inbred virgin female (Ludwig/Wistar/Olac) rats bearing tumors induced with NMU
  • Dosages: ~5 mg/kg/day
  • Administration: Injection s.c.
    (Only for Reference)

Solubility (25°C)

In vitro DMSO 23 mg/mL (76.05 mM)
Water Insoluble
Ethanol Insoluble
In vivo Add solvents to the product individually and in order(Data is from Selleck tests instead of citations):
2% DMSO+30% PEG 300+2% Tween 80+ddH2O
For best results, use promptly after mixing.
3mg/mL

* Please note that Selleck tests the solubility of all compounds in-house, and the actual solubility may differ slightly from published values. This is normal and is due to slight batch-to-batch variations.

Chemical Information

Molecular Weight 302.4
Formula

C17H22N2O3

CAS No. 58880-19-6
Storage powder
in solvent
Synonyms N/A

In vivo Formulation Calculator (Clear solution)

Step 1: Enter information below (Recommended: An additional animal making an allowance for loss during the experiment)
Dosage mg/kg Average weight of animals g Dosing volume per animal ul Number of animals
Step 2: Enter the in vivo formulation ()
% DMSO % % Tween 80 % ddH2O
CalculateReset

Bio Calculators

Molarity Calculator

Molarity Calculator

Calculate the mass, volume or concentration required for a solution. The Selleck molarity calculator is based on the following equation:

Mass (mg) = Concentration (mM) × Volume (mL) × Molecular Weight (g/mol)

  • Mass
    Concentration
    Volume
    Molecular Weight

*When preparing stock solutions, please always use the batch-specific molecular weight of the product found on the via label and MSDS / COA (available on product pages).

Dilution Calculator

Dilution Calculator

Calculate the dilution required to prepare a stock solution. The Selleck dilution calculator is based on the following equation:

Concentration (start) x Volume (start) = Concentration (final) x Volume (final)

This equation is commonly abbreviated as: C1V1 = C2V2 ( Input Output )

  • C1
    V1
    C2
    V2

* When preparing stock solutions always use the batch-specific molecular weight of the product found on the vial label and MSDS / COA (available online).

The Serial Dilution Calculator Equation

  • Serial Dilutions

  • Computed Result

  • C1=C0/X C1: LOG(C1):
    C2=C1/X C2: LOG(C2):
    C3=C2/X C3: LOG(C3):
    C4=C3/X C4: LOG(C4):
    C5=C4/X C5: LOG(C5):
    C6=C5/X C6: LOG(C6):
    C7=C6/X C7: LOG(C7):
    C8=C7/X C8: LOG(C8):
Molecular Weight Calculator

Molecular Weight Calculator

Enter the chemical formula of a compound to calculate its molar mass and elemental composition:

Total Molecular Weight: g/mol

Tip: Chemical formula is case sensitive. C10H16N2O2 c10h16n2o2

Instructions to calculate molar mass (molecular weight) of a chemical compound:

To calculate molar mass of a chemical compound, please enter its chemical formula and click 'Calculate'.

Definitions of molecular mass, molecular weight, molar mass and molar weight:

Molecular mass (molecular weight) is the mass of one molecule of a substance and is expressed in the unified atomic mass units (u). (1 u is equal to 1/12 the mass of one atom of carbon-12)
Molar mass (molar weight) is the mass of one mole of a substance and is expressed in g/mol.

Molarity Calculator

Mass Concentration Volume Molecular Weight

Clinical Trial Information

NCT Number Recruitment interventions Conditions Sponsor/Collaborators Start Date Phases
NCT03901053 Recruiting Device: Reaktiv AFO|Device: PhatBrace AFO Foot Injuries and Disorders Jason Wilken|Minneapolis Veterans Affairs Medical Center|Walter Reed National Military Medical Center|Henry M. Jackson Foundation for the Advancement of Military Medicine|Center for Veterans Research and Education|University of Delaware|Johns Hopkins Bloomberg School of Public Health|University of Iowa February 27 2020 Not Applicable
NCT03887650 Recruiting Drug: Liposomal Bupivicaine 1.3%|Drug: Bupivacaine 0.5% Post-operative Pain|Total Shoulder Arthroplasty|Osteoarthritis of the Shoulder|Pain Management Hartford Hospital January 14 2019 Phase 4
NCT03838926 Recruiting Drug: Trichostatin A Relapsed or Refractory Hematologic Malignancies Vanda Pharmaceuticals September 27 2018 Phase 1

Tech Support

Answers to questions you may have can be found in the inhibitor handling instructions. Topics include how to prepare stock solutions, how to store inhibitors, and issues that need special attention for cell-based assays and animal experiments.

Handling Instructions

Tel: +1-832-582-8158 Ext:3

If you have any other enquiries, please leave a message.

  • * Indicates a Required Field

Frequently Asked Questions

  • Question 1:

    I would like to obtain the enantiomers of TSA, as separate chemicals: R-TSA and S-TSA. Do you have any ideas?

  • Answer:

    Our S1045 Trichostatin A (TSA) is R enantiomer.

HDAC Signaling Pathway Map

HDAC Inhibitors with Unique Features

Related HDAC Products

Tags: buy Trichostatin A|Trichostatin A ic50|Trichostatin A price|Trichostatin A cost|Trichostatin A solubility dmso|Trichostatin A purchase|Trichostatin A manufacturer|Trichostatin A research buy|Trichostatin A order|Trichostatin A mouse|Trichostatin A chemical structure|Trichostatin A mw|Trichostatin A molecular weight|Trichostatin A datasheet|Trichostatin A supplier|Trichostatin A in vitro|Trichostatin A cell line|Trichostatin A concentration|Trichostatin A nmr|Trichostatin A in vivo|Trichostatin A clinical trial|Trichostatin A inhibitor|Trichostatin A Epigenetics inhibitor
×
Cell Lines Assay Type Concentration Incubation Time Formulation Activity Description PMID